Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy

Heinrich-Heine University, Duesseldorf328 enrolled

Overview

A study to examine whether an antipsychotic combination treatment of olanzapine and amisulpride is more effective than olanzapine and amisulpride alone.

Polypharmacy in antipsychotic therapy is an important issue when treating patients with schizophrenia. It is not well confirmed that a combination of two antipsychotic drugs lead to therapeutic benefit in contrast to monotherapy. However there is a highly frequent practice of combining atypical non-clozapine treatment that could be due to potential benefits when seeking alternatives to a high rate of non-response in acute phase. Therefore there is a need for further trials of sufficient power to address efficacy and safety issues of this regimen. Combining two selected atypical drugs in a complementary way may minimize side-effects and enhance efficacy. In order to specify these advantages it is intend to examine approaches to combination treatment: Amisulpride and olanzapine show complementing receptor binding profiles and have shown to have efficacy and good tolerability when administered in combination in retrospective studies. The object of this trial is to study whether acutely ill patients with combination of amisulpride and olanzapine are more frequently in symptomatic remission after 8 weeks than those with olanzapine or amisulpride monotherapy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

328

Conditions

Schizophrenia Schizoaffective Disorder

Interventions

OlanzapineDRUG

Coated tablet 5-20 mg milligram(s) per day for 16 weeks

AmisulprideDRUG

200-800 mg milligram(s)per day for 16 weeks

Olanzapine and AmisulprideDRUG

Zyprexa: Coated tablet 5-20 mg milligram(s) per day for 16 weeks Amisulpride: Coated tablet 200-800 mg milligram(s)per day for 16 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with schizophrenia and schizoaffective disorder according to International Classification of Diseases (ICD-10); * age 18-65; * Positive and Negative Symptom Scale Total-Score ≥ 70 and two items of the positive symptom subscale ≥4. * voluntary treatment after written informed consent * legal capacity * exclusion of pregnancy by laboratory test (Beta HCG) Exclusion Criteria: * participation in other interventional studies with drugs or medical devices * first episode patients * physical disease that might have effects on the conduct or evaluation of the trial * contraindications to medication according to experts information * oversensitivity to active substance or other component of the drugs used * known clozapine resistance * suicidal ideation * pregnancy or lactation * which of pregnancy or absence save contraception * dependency to sponsor or investigator * institutionalization through judicial or regulatory order * oversensitivity to placebo (mannite/aerosil)

Locations (21)

RWTH Aachen

Aachen, Germany

Outcomes

Primary Outcomes

Symptomatic improvement of schizophrenia after 8 weeks of treatment in comparison to time of inclusion of patient measured py Positive and Negative Symptom Scale (PANSS)

Whether there is a symptomatic improvement of schizophrenia after 8 weeks of treatment in comparison to time of inclusion of patient measured py Positive and Negative Symptom Scale (PANSS)

Time frame: 8 weeks

Secondary Outcomes

Symptomatic improvement of schizophrenia after 16 weeks of treatment in comparison to time of inclusion of patient measured py PANSS total score reduction

To study whether a combination treatment of olanzapine and amisulpride show a PANSS total score reduction from baseline to week 16.

Time frame: 16 weeks.

Symptomatic improvement of schizophrenia from baseline to week 2 up to week 16 measured by PANSS total score reduction.

Whether a combination treatment of olanzapine and amisulpride show a PANSS total score reduction from baseline to every 2 weeks up to week 16.

Time frame: Every 2 weeks up to week 16.

PANSS total score reduction from baseline to week 2 as a predictor of the change after 8 weeks

Whether a change of PANSS total score reduction from baseline to week 2 is a predictor of the change after 8 weeks

Time frame: 8 weeks

Serious adverse drug reactions

Frequency and severity of serious adverse drug reactions

Time frame: 16 weeks

Change of clinical condition measured by Clinical Global Impression Scale (CGI scale)

Whether there is a change of clinical condition measured by Clinical Global Impression Scale (CGI scale)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.